Frida from Poland

Registered at the short selling broker eToro, 3 minutes ago.

» Try eToro you too
75% of retail investor accounts lose money when trading CFDs with etoro.
Don't show again

Esperion Therapeutics, Inc. (ESPR) shares information

Esperion Therapeutics Inc.


24h Change

-4.49 %

ESPR

Live rate: Market closed

Stock data per Friday 15 Jan, 2021

ESPR
NASDAQ/NMS (GLOBAL MARKET)
26.75
26.32
25.55
-1.2 (-4.49%)
US Market is closed

Live Stock price in graph for Esperion Therapeutics Inc. (ESPR)

  • Latest Volume

    1,072,731 (-4.8 %)

  • Volume prev. day

    1,126,876

  • Avg. daily volume

    780,929

  • Market cap

    712,247,794

  • P/E ratio

    n/a

  • Today high

    26.84 USD

  • Today low

    25.54 USD

  • 52 week high

    73.84 USD

  • 52 week low

    24.2 USD

  • YTD Change

    n/a

Quick links

 

Latest news about Esperion Therapeutics Inc.

Below you can find the most recent news posts about Esperion Therapeutics Inc., primarily from US and UK based news sources.

Why Novartis, BioVie, Esperion And VBI Are Moving Today

Friday, 15 January 2021, 17:47:09
Esperion Therapeutics (NASDAQ: ESPR ) shares are trading lower … Full story available on Benzinga.com
— Benzinga


Why BioLine, Esperion And More Are Moving Today

Wednesday, 16 December 2020, 17:40:11
Esperion Therapeutics (NASDAQ: ESPR ) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Combination with NUSTENDI. Esprit Holdings is an international fashion brand whose operations include Retail, Wholesale and Licensing. It produces garments that are sold at its directly managed retail outlets. Esperion Therapeutics shares were trading down 1.77% at $27.67. The stock has a 52-week high of $76.98 and a 52-week low of $23.90. Anika Therapeutics (NASDAQ: ANIK ) shares are trading higher after Barrington Research upgraded the stock from Market … Full story available on Benzinga.com
— Benzinga


The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings

Wednesday, 4 November 2020, 14:21:27
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 3) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) BioLineRx ADR Representing 15 Ord Shs (NASDAQ: BLRX )(reacted to positive readout for its stem cell therapy to treat cancer) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(reacted to its quarterly results) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) ( reported strong results for the third quarter) Immunovant Inc (NASDAQ: IMVT ) Scholar Rock Holding Corp (NASDAQ: SRRK ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 3) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aprea Therapeutics Inc (NASDAQ: APRE ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Benitec Biopharma Inc (NASDAQ: BNTC ) Esperion Therapeutics Inc (NASDAQ: ESPR ) (reacted to its quarterly results) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Jaguar Health Inc (NASDAQ: JAGX ) Liminal BioSciences Inc (NASDAQ: LMNL ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Opthea Spon (NASDAQ: OPT ) Silence Therapeutics ADR (NASDAQ: SLN ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Bristol-Myers Squibb Says Antitrust Waiting Period For Proposed Myokardia Acquisition Expires Bristol-Myers Squibb Co (NYSE: BMY ) said the waiting period under the HSR Act in connection with its previously announced tender offer to acquire …
— Benzinga


Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q3 2020 Results – Earnings Call Transcript

Tuesday, 3 November 2020, 03:58:03
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2020 Earnings Conference Call November 02, 2020 4:30 PM ET Company Participants Ben Church – Investor Relations and Corporate Communications Tim Mayleben – President & Chief Executive Officer Mark Glickman – Chief Commercial Officer Rick Bartram – Chief Financial Officer Conference Call Participants Michael Yee – Jefferies Geoff Meacham – Bank of America Joseph Thome – Cowen and Company Marty Auster – Credit Suisse Roy Buchanan – JMP Securities Derek Archila – Stifel Gil Blum – Needham & Company Julian Harrison – BTIG Paul Choi – Goldman Sachs Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome.
— Seeking Alpha


Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by BidaskClub

Tuesday, 20 October 2020, 04:38:41
BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a sell rating to a hold rating in a research report sent to investors on Saturday morning, BidAskClub reports. Other research analysts also recently issued research reports about the company. JPMorgan Chase & Co. began coverage on Esperion Therapeutics in a research note on Tuesday, September 29th. […]
— Stock Observer


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €200
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have ESPR available or trade one of the many other CFD stocks they have.
Risk warning: 75% of retail investor accounts lose money when trading CFDs with Capital.